These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12076502)

  • 1. Rofecoxib for the treatment of rheumatoid arthritis.
    Garner S; Fidan D; Frankish R; Judd M; Towheed T; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2002; (2):CD003685. PubMed ID: 12076502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rofecoxib for the treatment of rheumatoid arthritis.
    Garner S; Fidan D; Frankish R; Judd M; Towheed T; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2002; (3):CD003685. PubMed ID: 12137705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rofecoxib for rheumatoid arthritis.
    Garner SE; Fidan DD; Frankish RR; Judd MG; Towheed TE; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD003685. PubMed ID: 15674912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib for rheumatoid arthritis.
    Garner S; Fidan D; Frankish R; Judd M; Shea B; Towheed T; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2002; (4):CD003831. PubMed ID: 12519610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rofecoxib for osteoarthritis.
    Garner SE; Fidan DD; Frankish R; Maxwell L
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD005115. PubMed ID: 15654705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WITHDRAWN: Celecoxib for rheumatoid arthritis.
    Garner SE; Fidan D; Frankish RR; Judd M; Shea B; Towheed T; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003831. PubMed ID: 28598564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
    Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J;
    Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
    Jüni P; Nartey L; Reichenbach S; Sterchi R; Dieppe PA; Egger M
    Lancet; 2004 Dec 4-10; 364(9450):2021-9. PubMed ID: 15582059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
    N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Konstam MA; Weir MR; Reicin A; Shapiro D; Sperling RS; Barr E; Gertz BJ
    Circulation; 2001 Nov; 104(19):2280-8. PubMed ID: 11696466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
    Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP;
    Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
    Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
    Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
    Reiff A; Lovell DJ; Adelsberg JV; Kiss MH; Goodman S; Zavaler MF; Chen PY; Bolognese JA; Cavanaugh P; Reicin AS; Giannini EH
    J Rheumatol; 2006 May; 33(5):985-95. PubMed ID: 16583464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single dose oral rofecoxib for postoperative pain.
    Barden J; Edwards J; Moore RA; McQuay HJ
    Cochrane Database Syst Rev; 2004; (1):CD004604. PubMed ID: 14974074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.
    Graham DY; Jewell NP; Chan FK
    Am J Med Sci; 2011 Nov; 342(5):356-64. PubMed ID: 21986300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetaminophen for osteoarthritis.
    Towheed TE; Judd MJ; Hochberg MC; Wells G
    Cochrane Database Syst Rev; 2003; (2):CD004257. PubMed ID: 12804508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.